Gregory Forlenza
Concepts (235)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Insulin Infusion Systems | 94 | 2026 | 488 | 17.210 |
Why?
| | Diabetes Mellitus, Type 1 | 117 | 2026 | 3930 | 12.350 |
Why?
| | Insulin | 95 | 2026 | 2524 | 9.350 |
Why?
| | Hypoglycemic Agents | 91 | 2026 | 1411 | 9.120 |
Why?
| | Blood Glucose Self-Monitoring | 79 | 2026 | 704 | 8.980 |
Why?
| | Pancreas, Artificial | 31 | 2025 | 97 | 8.710 |
Why?
| | Blood Glucose | 106 | 2026 | 2357 | 8.470 |
Why?
| | Hypoglycemia | 36 | 2026 | 489 | 5.660 |
Why?
| | Hyperglycemia | 15 | 2023 | 381 | 3.070 |
Why?
| | Hematopoietic Stem Cell Transplantation | 5 | 2022 | 700 | 1.920 |
Why?
| | Diabetes Mellitus | 10 | 2025 | 1101 | 1.680 |
Why?
| | Monitoring, Ambulatory | 5 | 2018 | 88 | 1.600 |
Why?
| | Islets of Langerhans Transplantation | 5 | 2024 | 71 | 1.590 |
Why?
| | Child | 67 | 2026 | 22638 | 1.470 |
Why?
| | Adolescent | 68 | 2026 | 22451 | 1.440 |
Why?
| | Algorithms | 18 | 2025 | 1843 | 1.350 |
Why?
| | Pancreatectomy | 5 | 2024 | 289 | 1.350 |
Why?
| | Humans | 149 | 2026 | 145625 | 1.310 |
Why?
| | Insulin-Secreting Cells | 3 | 2023 | 393 | 1.250 |
Why?
| | Pancreatitis, Chronic | 4 | 2024 | 64 | 1.150 |
Why?
| | Young Adult | 40 | 2026 | 14240 | 1.090 |
Why?
| | Biomedical Technology | 2 | 2019 | 49 | 1.090 |
Why?
| | Diabetes Mellitus, Type 2 | 9 | 2026 | 2623 | 1.030 |
Why?
| | Verapamil | 2 | 2023 | 37 | 0.970 |
Why?
| | Patient Education as Topic | 3 | 2021 | 769 | 0.950 |
Why?
| | Adult | 58 | 2026 | 40821 | 0.920 |
Why?
| | Male | 66 | 2026 | 73014 | 0.830 |
Why?
| | Technology | 5 | 2023 | 100 | 0.770 |
Why?
| | Female | 64 | 2026 | 79080 | 0.760 |
Why?
| | Telemedicine | 3 | 2022 | 956 | 0.760 |
Why?
| | Calcium Channel Blockers | 1 | 2023 | 165 | 0.730 |
Why?
| | Caregivers | 3 | 2025 | 1079 | 0.680 |
Why?
| | Child, Preschool | 19 | 2025 | 11888 | 0.670 |
Why?
| | Insulin Lispro | 4 | 2026 | 44 | 0.660 |
Why?
| | Self-Management | 2 | 2026 | 207 | 0.650 |
Why?
| | Lymphoma | 1 | 2023 | 251 | 0.650 |
Why?
| | Glucose | 9 | 2024 | 1051 | 0.640 |
Why?
| | Treatment Outcome | 20 | 2026 | 11744 | 0.600 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 299 | 0.590 |
Why?
| | Patient Dropouts | 1 | 2020 | 65 | 0.580 |
Why?
| | Patient Satisfaction | 3 | 2024 | 698 | 0.570 |
Why?
| | Personal Satisfaction | 1 | 2020 | 218 | 0.550 |
Why?
| | Diabetic Ketoacidosis | 5 | 2024 | 212 | 0.540 |
Why?
| | Eczema | 1 | 2018 | 66 | 0.520 |
Why?
| | Transplantation Conditioning | 1 | 2019 | 191 | 0.520 |
Why?
| | Betacoronavirus | 1 | 2020 | 288 | 0.500 |
Why?
| | Diffusion of Innovation | 1 | 2017 | 96 | 0.480 |
Why?
| | Diabetic Retinopathy | 2 | 2024 | 211 | 0.480 |
Why?
| | Retrospective Studies | 14 | 2026 | 17291 | 0.450 |
Why?
| | Machine Learning | 2 | 2025 | 590 | 0.450 |
Why?
| | Endocrine Glands | 1 | 2015 | 14 | 0.450 |
Why?
| | Insulin, Regular, Human | 7 | 2023 | 47 | 0.440 |
Why?
| | Aged | 22 | 2026 | 26251 | 0.440 |
Why?
| | Quality of Life | 4 | 2024 | 3187 | 0.440 |
Why?
| | Endocrine System Diseases | 1 | 2015 | 35 | 0.430 |
Why?
| | Transplantation, Autologous | 4 | 2024 | 303 | 0.430 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 387 | 0.430 |
Why?
| | Coronavirus Infections | 1 | 2020 | 379 | 0.430 |
Why?
| | C-Peptide | 3 | 2025 | 191 | 0.420 |
Why?
| | Exercise | 9 | 2025 | 2206 | 0.410 |
Why?
| | Artificial Intelligence | 1 | 2019 | 385 | 0.410 |
Why?
| | Fanconi Anemia | 1 | 2013 | 11 | 0.410 |
Why?
| | United States | 16 | 2026 | 16041 | 0.400 |
Why?
| | Dwarfism | 1 | 2013 | 15 | 0.400 |
Why?
| | Middle Aged | 26 | 2026 | 36359 | 0.400 |
Why?
| | Cross-Over Studies | 7 | 2026 | 612 | 0.400 |
Why?
| | Growth Hormone | 1 | 2013 | 91 | 0.390 |
Why?
| | Awareness | 2 | 2026 | 113 | 0.390 |
Why?
| | Skin | 1 | 2018 | 701 | 0.390 |
Why?
| | Suicide | 1 | 2020 | 638 | 0.370 |
Why?
| | Blindness | 1 | 2012 | 51 | 0.360 |
Why?
| | Sequence Analysis, DNA | 1 | 2015 | 771 | 0.360 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2015 | 538 | 0.340 |
Why?
| | Pandemics | 1 | 2020 | 1700 | 0.340 |
Why?
| | Angiogenesis Inhibitors | 1 | 2012 | 238 | 0.330 |
Why?
| | Biosensing Techniques | 2 | 2025 | 142 | 0.320 |
Why?
| | Calibration | 3 | 2020 | 154 | 0.320 |
Why?
| | Lingual Frenum | 1 | 2010 | 2 | 0.320 |
Why?
| | Tongue Diseases | 1 | 2010 | 9 | 0.320 |
Why?
| | Failure to Thrive | 1 | 2010 | 27 | 0.310 |
Why?
| | Cardiovascular Diseases | 1 | 2022 | 2218 | 0.310 |
Why?
| | Epidemics | 1 | 2011 | 97 | 0.310 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2012 | 543 | 0.310 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2016 | 1754 | 0.310 |
Why?
| | Medicaid | 3 | 2022 | 472 | 0.300 |
Why?
| | Medicare | 3 | 2025 | 907 | 0.300 |
Why?
| | Models, Biological | 1 | 2016 | 1758 | 0.290 |
Why?
| | Meals | 5 | 2026 | 130 | 0.280 |
Why?
| | Double-Blind Method | 4 | 2023 | 2064 | 0.280 |
Why?
| | Infant | 6 | 2023 | 10093 | 0.280 |
Why?
| | Skiing | 2 | 2019 | 50 | 0.260 |
Why?
| | Follow-Up Studies | 5 | 2021 | 5397 | 0.260 |
Why?
| | Adolescent Nutritional Physiological Phenomena | 2 | 2017 | 29 | 0.250 |
Why?
| | Inventions | 2 | 2018 | 18 | 0.250 |
Why?
| | Prospective Studies | 7 | 2025 | 8087 | 0.250 |
Why?
| | Insurance Coverage | 2 | 2025 | 246 | 0.240 |
Why?
| | Endocrinology | 2 | 2018 | 77 | 0.230 |
Why?
| | Feasibility Studies | 6 | 2026 | 1125 | 0.230 |
Why?
| | Insulin Aspart | 2 | 2022 | 30 | 0.230 |
Why?
| | Outpatients | 2 | 2021 | 437 | 0.220 |
Why?
| | Injections, Subcutaneous | 3 | 2020 | 170 | 0.220 |
Why?
| | Overweight | 2 | 2023 | 613 | 0.220 |
Why?
| | Risk Factors | 5 | 2020 | 10840 | 0.220 |
Why?
| | Postoperative Complications | 2 | 2015 | 2962 | 0.210 |
Why?
| | Body Height | 2 | 2017 | 202 | 0.210 |
Why?
| | Mutation | 1 | 2015 | 4082 | 0.200 |
Why?
| | Equipment Failure | 3 | 2018 | 111 | 0.180 |
Why?
| | Insulins | 1 | 2023 | 39 | 0.180 |
Why?
| | Eligibility Determination | 1 | 2022 | 72 | 0.180 |
Why?
| | Patient Safety | 1 | 2025 | 351 | 0.170 |
Why?
| | Pediatrics | 2 | 2020 | 1122 | 0.170 |
Why?
| | Automobile Driving | 1 | 2023 | 156 | 0.160 |
Why?
| | Infusion Pumps, Implantable | 1 | 2020 | 26 | 0.160 |
Why?
| | Computer Systems | 1 | 2020 | 54 | 0.150 |
Why?
| | Smartphone | 2 | 2019 | 103 | 0.150 |
Why?
| | Europe | 3 | 2025 | 420 | 0.150 |
Why?
| | Sports | 2 | 2019 | 216 | 0.150 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2019 | 74 | 0.150 |
Why?
| | Fatal Outcome | 1 | 2020 | 302 | 0.150 |
Why?
| | Reproducibility of Results | 4 | 2024 | 3396 | 0.140 |
Why?
| | Prevalence | 3 | 2023 | 2852 | 0.140 |
Why?
| | Clinical Alarms | 1 | 2017 | 11 | 0.130 |
Why?
| | Software | 2 | 2021 | 673 | 0.130 |
Why?
| | Night Terrors | 1 | 2017 | 1 | 0.130 |
Why?
| | Insulinoma | 1 | 2017 | 30 | 0.130 |
Why?
| | Device Approval | 1 | 2017 | 19 | 0.130 |
Why?
| | Diet, Diabetic | 1 | 2017 | 33 | 0.130 |
Why?
| | Voluntary Health Agencies | 1 | 2016 | 6 | 0.120 |
Why?
| | Survival Analysis | 1 | 2020 | 1372 | 0.120 |
Why?
| | Adrenal Hyperplasia, Congenital | 1 | 2017 | 39 | 0.120 |
Why?
| | Program Evaluation | 1 | 2021 | 945 | 0.120 |
Why?
| | United States Food and Drug Administration | 1 | 2017 | 207 | 0.120 |
Why?
| | Obesity | 3 | 2023 | 3123 | 0.120 |
Why?
| | Pancreaticoduodenectomy | 1 | 2017 | 149 | 0.120 |
Why?
| | Statistics as Topic | 1 | 2016 | 277 | 0.110 |
Why?
| | Abdominal Pain | 1 | 2017 | 148 | 0.110 |
Why?
| | Hypophosphatasia | 1 | 2015 | 5 | 0.110 |
Why?
| | Age Factors | 3 | 2018 | 3321 | 0.110 |
Why?
| | Drug Overdose | 1 | 2020 | 376 | 0.110 |
Why?
| | Automation | 2 | 2025 | 104 | 0.110 |
Why?
| | Drug Delivery Systems | 1 | 2018 | 377 | 0.110 |
Why?
| | Alkaline Phosphatase | 1 | 2015 | 144 | 0.110 |
Why?
| | History, 21st Century | 2 | 2025 | 224 | 0.100 |
Why?
| | Autografts | 1 | 2014 | 56 | 0.100 |
Why?
| | Pilot Projects | 2 | 2020 | 1878 | 0.100 |
Why?
| | Health Services Accessibility | 1 | 2022 | 1101 | 0.100 |
Why?
| | History, 20th Century | 2 | 2025 | 330 | 0.100 |
Why?
| | Choristoma | 1 | 2013 | 20 | 0.100 |
Why?
| | Glucose Clamp Technique | 1 | 2014 | 199 | 0.100 |
Why?
| | Primary Ovarian Insufficiency | 1 | 2013 | 40 | 0.100 |
Why?
| | Postoperative Period | 1 | 2014 | 344 | 0.100 |
Why?
| | Infusions, Intravenous | 1 | 2014 | 429 | 0.100 |
Why?
| | Pituitary Gland | 1 | 2013 | 148 | 0.100 |
Why?
| | Clinical Decision-Making | 1 | 2016 | 364 | 0.090 |
Why?
| | Graft Survival | 1 | 2015 | 508 | 0.090 |
Why?
| | Allografts | 1 | 2013 | 148 | 0.090 |
Why?
| | Bionics | 2 | 2022 | 14 | 0.090 |
Why?
| | Surveys and Questionnaires | 2 | 2024 | 6050 | 0.090 |
Why?
| | Patient Compliance | 1 | 2017 | 587 | 0.090 |
Why?
| | Clinical Protocols | 1 | 2014 | 279 | 0.090 |
Why?
| | Graft Rejection | 1 | 2015 | 504 | 0.090 |
Why?
| | Adolescent Behavior | 1 | 2017 | 486 | 0.090 |
Why?
| | Genetic Testing | 1 | 2015 | 491 | 0.090 |
Why?
| | Quality Improvement | 1 | 2021 | 1325 | 0.090 |
Why?
| | Pituitary Neoplasms | 1 | 2013 | 190 | 0.090 |
Why?
| | Adipose Tissue | 1 | 2016 | 641 | 0.090 |
Why?
| | Body Mass Index | 2 | 2017 | 2446 | 0.090 |
Why?
| | Prognosis | 2 | 2020 | 4331 | 0.080 |
Why?
| | Age of Onset | 1 | 2012 | 557 | 0.080 |
Why?
| | Longitudinal Studies | 3 | 2024 | 3005 | 0.080 |
Why?
| | Biomedical Research | 1 | 2016 | 724 | 0.080 |
Why?
| | Activities of Daily Living | 3 | 2017 | 438 | 0.070 |
Why?
| | Critical Illness | 1 | 2016 | 905 | 0.070 |
Why?
| | Global Health | 1 | 2012 | 402 | 0.070 |
Why?
| | Consensus | 2 | 2022 | 465 | 0.070 |
Why?
| | Pancreatic Neoplasms | 1 | 2017 | 944 | 0.070 |
Why?
| | Biomarkers | 1 | 2020 | 4329 | 0.070 |
Why?
| | Electronic Health Records | 1 | 2016 | 1208 | 0.070 |
Why?
| | Aged, 80 and over | 3 | 2026 | 8351 | 0.070 |
Why?
| | Guideline Adherence | 1 | 2012 | 585 | 0.070 |
Why?
| | Case-Control Studies | 1 | 2015 | 3633 | 0.070 |
Why?
| | Equipment Design | 2 | 2019 | 519 | 0.070 |
Why?
| | Societies, Medical | 2 | 2024 | 901 | 0.060 |
Why?
| | Hospitalization | 3 | 2024 | 2468 | 0.060 |
Why?
| | Infant, Newborn | 1 | 2019 | 6449 | 0.060 |
Why?
| | Cold Temperature | 2 | 2019 | 207 | 0.060 |
Why?
| | Weight Gain | 1 | 2010 | 561 | 0.060 |
Why?
| | Breast Feeding | 1 | 2010 | 447 | 0.060 |
Why?
| | Disposable Equipment | 1 | 2026 | 24 | 0.060 |
Why?
| | Time Factors | 3 | 2025 | 7079 | 0.060 |
Why?
| | Incidence | 1 | 2012 | 2910 | 0.060 |
Why?
| | Seasons | 2 | 2019 | 535 | 0.060 |
Why?
| | Practice Guidelines as Topic | 1 | 2012 | 1581 | 0.050 |
Why?
| | Risk | 2 | 2017 | 917 | 0.050 |
Why?
| | Child Abuse | 1 | 2010 | 545 | 0.050 |
Why?
| | Mass Screening | 1 | 2012 | 1300 | 0.050 |
Why?
| | Combined Modality Therapy | 2 | 2017 | 1269 | 0.050 |
Why?
| | Diet | 1 | 2011 | 1271 | 0.050 |
Why?
| | Bayes Theorem | 1 | 2025 | 424 | 0.050 |
Why?
| | Quality-Adjusted Life Years | 1 | 2023 | 119 | 0.050 |
Why?
| | Insulin Resistance | 1 | 2011 | 1247 | 0.050 |
Why?
| | Standard of Care | 1 | 2023 | 81 | 0.050 |
Why?
| | Pregnancy | 2 | 2025 | 7217 | 0.040 |
Why?
| | Reference Standards | 1 | 2021 | 176 | 0.040 |
Why?
| | Cohort Studies | 2 | 2025 | 6045 | 0.040 |
Why?
| | Intention to Treat Analysis | 1 | 2020 | 78 | 0.040 |
Why?
| | Cost-Benefit Analysis | 1 | 2023 | 632 | 0.040 |
Why?
| | Pancreas | 1 | 2022 | 342 | 0.040 |
Why?
| | Social Conditions | 1 | 2019 | 14 | 0.040 |
Why?
| | Inpatients | 1 | 2024 | 538 | 0.040 |
Why?
| | Disease Management | 1 | 2023 | 649 | 0.040 |
Why?
| | Equipment and Supplies | 1 | 2018 | 36 | 0.030 |
Why?
| | Health Personnel | 1 | 2025 | 750 | 0.030 |
Why?
| | International Cooperation | 1 | 2018 | 192 | 0.030 |
Why?
| | Postprandial Period | 1 | 2018 | 114 | 0.030 |
Why?
| | Virginia | 1 | 2017 | 57 | 0.030 |
Why?
| | Snacks | 1 | 2017 | 23 | 0.030 |
Why?
| | Mobile Applications | 1 | 2020 | 193 | 0.030 |
Why?
| | Reference Values | 1 | 2018 | 787 | 0.030 |
Why?
| | Colorado | 2 | 2017 | 4588 | 0.030 |
Why?
| | Ohio | 1 | 2017 | 136 | 0.030 |
Why?
| | Child Nutritional Physiological Phenomena | 1 | 2017 | 102 | 0.030 |
Why?
| | Minnesota | 1 | 2017 | 167 | 0.030 |
Why?
| | Accelerometry | 1 | 2017 | 123 | 0.030 |
Why?
| | Single-Blind Method | 1 | 2017 | 312 | 0.030 |
Why?
| | Hypertrophy | 1 | 2016 | 126 | 0.030 |
Why?
| | Food Preferences | 1 | 2017 | 126 | 0.030 |
Why?
| | Materials Testing | 1 | 2017 | 345 | 0.030 |
Why?
| | Healthcare Disparities | 1 | 2022 | 728 | 0.030 |
Why?
| | Child Behavior | 1 | 2017 | 234 | 0.030 |
Why?
| | Pain Measurement | 1 | 2017 | 567 | 0.030 |
Why?
| | Feeding Behavior | 1 | 2018 | 691 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2018 | 1370 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2017 | 2910 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2017 | 3917 | 0.010 |
Why?
|
|
Forlenza's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|